MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.
Guardant buys MetaSight for $59M upfront to acquire blood test tech
MetaSight uses metabolomics, lipidomics and proteomics mass spectrometry technologies to develop tests for specific diseases, including conditions outside of oncology.